In: Human Reproduction, 2017, vol. 32, no. 4, p. 820-831
|
In: Glycobiology, 2018, vol. 28, no. 9, p. 640-647
|
In: Scientific Reports, 2020, vol. 10, no. 1, p. 7078
Immunotherapies, such as checkpoint blockade of programmed cell death protein-1 (PD-1), have resulted in unprecedented improvements in survival for patients with lung cancer. Nonetheless, not all patients benefit equally and many issues remain unresolved, including the mechanisms of action and the possible effector function of immune cells from non-lymphoid lineages. The purpose of this...
|
In: Non-coding RNA, 2019, vol. 5, no. 3, p. 47
Diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) and follicular lymphoma (FL) are the most common B-cell lymphomas (BCL) in dogs. Recent investigations have demonstrated overlaps of these histotypes with the human counterparts, including clinical presentation, biologic behavior, tumor genetics, and treatment response. The molecular mechanisms that underlie canine BCL are...
|
In: International journal of molecular sciences, 2020, vol. 21, no. 3, p. 21 p
The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti- cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K/mTOR inhibitors as single agents and in combination in lymphomas. Clinical...
|
In: Cancer Immunology, Immunotherapy, 2014, vol. 63, no. 9, p. 925-938
|
In: European Journal of Nuclear Medicine and Molecular Imaging, 2014, vol. 41, no. 10, p. 1907-1915
|
In: Current Treatment Options in Neurology, 2014, vol. 16, no. 1, p. 1-14
|
In: European Journal of Clinical Microbiology & Infectious Diseases, 2014, vol. 33, no. 10, p. 1861-1867
|
In: European Journal of Nuclear Medicine and Molecular Imaging, 2006, vol. 33, no. 11, p. 1352-1363
|